Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Oral iron supplementation, IV iron administration.
- Who it may be relevant to
- Registry conditions: Anemia Complicating Pregnancy. Basic parameters: 18 years — 50 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation: A Randomized Controlled Trial
Overview
This study aims to address this evidence gap by comparing a step-up oral-first strategy with an early IV iron strategy in pregnant women diagnosed with anemia after 34 weeks of gestation.
Detailed description
Anemia during pregnancy remains a prevalent condition worldwide and is associated with a wide spectrum of adverse maternal and perinatal outcomes. Maternal anemia has been linked to increased risk of postpartum anemia, need for blood transfusion, impaired physical recovery after delivery, prolonged hospital stay, and reduced quality of life in the puerperium. From a healthcare system perspective, anemia management close to delivery has important implications for resource utilization and patient safety.
Recent National Guidelines have updated the diagnostic thresholds for anemia in pregnancy, defining anemia as hemoglobin (Hb) \<11 g/dL throughout gestation, including the third trimester. As a result, a growing number of women are diagnosed with anemia late in pregnancy, often after 34 weeks of gestation, when the time window for hematologic correction before delivery is limited.
In this setting, intravenous (IV) iron therapy is increasingly used to achieve a rapid increase in hemoglobin levels. While IV iron is effective and generally safe, it is associated with higher costs, need for monitored administration, and a small but non-negligible risk of hypersensitivity reactions. Importantly, the routine early use of IV iron in women diagnosed late in pregnancy is not uniformly supported by high-quality randomized evidence.
Oral iron remains the recommended first-line therapy for iron-deficiency anemia in pregnancy. However, the effectiveness of oral iron when initiated in late gestation is often questioned, leading to premature escalation to IV therapy without a documented trial of oral treatment. There is limited prospective evidence assessing whether oral iron, when promptly initiated after late diagnosis, can still achieve clinically meaningful hemoglobin improvements before delivery.
A step-up treatment strategy, consisting of oral iron as initial therapy with escalation to IV iron only in case of inadequate response, may represent a balanced approach that aligns with guideline recommendations, minimizes overtreatment, and preserves patient safety. However, this strategy has not been adequately evaluated in randomized controlled trials focusing specifically on late-diagnosed anemia.
This study aims to address this evidence gap by comparing a step-up oral-first strategy with an early IV iron strategy in pregnant women diagnosed with anemia after 34 weeks of gestation.
Interventions
- Drug Oral iron supplementation
Participants randomized to this group will begin oral iron therapy immediately after diagnosis. The formulation and dosage will follow institutional practice and guideline recommendations - Drug IV iron administration
Participants randomized to this group will receive IV iron within 7 days of diagnosis. The dose will be calculated based on body weight and estimated iron deficit. Oral iron supplementation is not mandated following IV administration.
Primary outcome measures
- Hemoglobin concentration (g/dL) measured at hospital admission for delivery. [Time frame: Delivery Hospitalization Day 1]
Secondary outcome measures (8)
- Hemoglobin concentration (g/dL) at 38+0 weeks of gestation [Time frame: At 38+0 weeks of gestation]
- Postpartum hemoglobin concentration (g/dL) [Time frame: Postpartum Day 1]
- Absolute change in hemoglobin [Time frame: At delivery hospitalization]
- Peripartum Blood Transfusion [Time frame: Peripeocedural]
- Postpartum Anemia [Time frame: Periprocedural]
- Quantitatively Assessed Blood Loss [Time frame: Periprocedural]
- Lenght of Hospital Stay (days) [Time frame: Periprocedural]
- Adverse Event associated with Iron Supplementation [Time frame: Periprocedural]
Eligibility criteria
Inclusion criteria
- • Women aged 18 years or older.
- Singleton pregnancy.
- Gestational age ≥34+0 weeks at the time of anemia diagnosis.
- Hemoglobin <11 g/dL measured as part of routine antenatal care.
- Ongoing antenatal follow-up at Policlinico Umberto I.
- Ability to understand study procedures and provide written informed consent.
Exclusion criteria
- • Known anemia not primarily due to iron deficiency.
- Known hemoglobinopathies.
- Severe anemia requiring immediate blood transfusion.
- Previous severe hypersensitivity reaction to IV iron formulations.
- Chronic hematologic disease.
- Acute infection or inflammatory condition at enrollment.
- Severe hepatic or renal impairment.
- Any condition judged by the investigator to make participation unsafe.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07485023 · PRAN-0001